Please assess the completion status of the following clinical trial:

Trial Title: DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or type 2 diabetes mellitus at screening~* Painful distal symmetric polyneuropathy~* At screening, a pain scale of ≥ 40 mm~Exclusion Criteria:~* HbA1c (National Glycohemoglobin Standardization Program) \> 10.0%

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo group (14 weeks)
- DS-5565 15mg (Type: EXPERIMENTAL): DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
- DS-5565 20 mg group (Type: EXPERIMENTAL): DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
- DS-5565 30 mg group (Type: EXPERIMENTAL): DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose

Based on this trial design, predict the completion outcome and termination type (if applicable).